Published in BMC Bioinformatics on July 30, 2010
Efficient modeling, simulation and coarse-graining of biological complexity with NFsim. Nat Methods (2010) 2.24
Modeling formalisms in Systems Biology. AMB Express (2011) 1.61
eSTGt: a programming and simulation environment for population dynamics. BMC Bioinformatics (2016) 1.39
Guidelines for visualizing and annotating rule-based models. Mol Biosyst (2011) 1.05
Rule-based modeling: a computational approach for studying biomolecular site dynamics in cell signaling systems. Wiley Interdiscip Rev Syst Biol Med (2013) 1.04
Multi-state modeling of biomolecules. PLoS Comput Biol (2014) 0.96
RuleBender: a visual interface for rule-based modeling. Bioinformatics (2011) 0.95
Phosphorylation site dynamics of early T-cell receptor signaling. PLoS One (2014) 0.93
The Simmune Modeler visual interface for creating signaling networks based on bi-molecular interactions. Bioinformatics (2013) 0.92
Toward a comprehensive language for biological systems. BMC Biol (2011) 0.92
A computational model for early events in B cell antigen receptor signaling: analysis of the roles of Lyn and Fyn. J Immunol (2012) 0.89
Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling. BMC Syst Biol (2012) 0.88
Hierarchical graphs for rule-based modeling of biochemical systems. BMC Bioinformatics (2011) 0.87
Exact hybrid particle/population simulation of rule-based models of biochemical systems. PLoS Comput Biol (2014) 0.87
Rule-based modelling and simulation of biochemical systems with molecular finite automata. IET Syst Biol (2010) 0.86
The Process-Interaction-Model: a common representation of rule-based and logical models allows studying signal transduction on different levels of detail. BMC Bioinformatics (2012) 0.83
The efficiency of reactant site sampling in network-free simulation of rule-based models for biochemical systems. Phys Biol (2011) 0.83
Pleomorphic ensembles: formation of large clusters composed of weakly interacting multivalent molecules. Biophys J (2013) 0.82
Modeling for (physical) biologists: an introduction to the rule-based approach. Phys Biol (2015) 0.81
Leveraging modeling approaches: reaction networks and rules. Adv Exp Med Biol (2012) 0.80
SpringSaLaD: A Spatial, Particle-Based Biochemical Simulation Platform with Excluded Volume. Biophys J (2016) 0.78
Analytical reduction of combinatorial complexity arising from multiple protein modification sites. J R Soc Interface (2015) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Signaling--2000 and beyond. Cell (2000) 11.78
Stochastic simulation of chemical kinetics. Annu Rev Phys Chem (2007) 7.59
Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol (2006) 7.25
Physicochemical modelling of cell signalling pathways. Nat Cell Biol (2006) 4.34
Cell signaling in space and time: where proteins come together and when they're apart. Science (2009) 3.88
Rules for modeling signal-transduction systems. Sci STKE (2006) 3.86
Rule-based modeling of biochemical systems with BioNetGen. Methods Mol Biol (2009) 3.47
BioNetGen: software for rule-based modeling of signal transduction based on the interactions of molecular domains. Bioinformatics (2004) 3.32
Automatic generation of cellular reaction networks with Moleculizer 1.0. Nat Biotechnol (2005) 3.26
Detailed simulations of cell biology with Smoldyn 2.1. PLoS Comput Biol (2010) 2.72
Virtual Cell modelling and simulation software environment. IET Syst Biol (2008) 2.43
Internal coarse-graining of molecular systems. Proc Natl Acad Sci U S A (2009) 2.37
A network model of early events in epidermal growth factor receptor signaling that accounts for combinatorial complexity. Biosystems (2005) 2.36
The complexity of complexes in signal transduction. Biotechnol Bioeng (2003) 2.20
Key role of local regulation in chemosensing revealed by a new molecular interaction-based modeling method. PLoS Comput Biol (2006) 2.13
Molecular machines or pleiomorphic ensembles: signaling complexes revisited. J Biol (2009) 2.07
Predicting temporal fluctuations in an intracellular signalling pathway. J Theor Biol (1998) 1.84
Investigation of early events in Fc epsilon RI-mediated signaling using a detailed mathematical model. J Immunol (2003) 1.78
Kinetic Monte Carlo method for rule-based modeling of biochemical networks. Phys Rev E Stat Nonlin Soft Matter Phys (2008) 1.76
Programming with models: modularity and abstraction provide powerful capabilities for systems biology. J R Soc Interface (2009) 1.69
Exact model reduction of combinatorial reaction networks. BMC Syst Biol (2008) 1.36
Domain-oriented reduction of rule-based network models. IET Syst Biol (2008) 1.29
Combinatorial complexity and dynamical restriction of network flows in signal transduction. Syst Biol (Stevenage) (2005) 1.27
Reduced modeling of signal transduction - a modular approach. BMC Bioinformatics (2007) 1.27
Pairing computation with experimentation: a powerful coupling for understanding T cell signalling. Nat Rev Immunol (2010) 1.25
Efficient stochastic simulation of reaction-diffusion processes via direct compilation. Bioinformatics (2009) 1.23
Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest (2007) 1.22
Equilibrium theory for the clustering of bivalent cell surface receptors by trivalent ligands. Application to histamine release from basophils. Biophys J (1984) 1.21
Aggregation of membrane proteins by cytosolic cross-linkers: theory and simulation of the LAT-Grb2-SOS1 system. Biophys J (2009) 1.19
Simulation of large-scale rule-based models. Bioinformatics (2009) 1.18
Modeling multivalent ligand-receptor interactions with steric constraints on configurations of cell-surface receptor aggregates. Biophys J (2010) 1.09
Modeling the early signaling events mediated by FcepsilonRI. Mol Immunol (2002) 1.05
Structure-based kinetic models of modular signaling protein function: focus on Shp2. Biophys J (2007) 1.03
Faster Monte Carlo simulations. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1995) 0.96
Computational models of tandem SRC homology 2 domain interactions and application to phosphoinositide 3-kinase. J Biol Chem (2008) 0.95
Current challenges in quantitative modeling of epidermal growth factor signaling. FEBS Lett (2005) 0.94
The complexity of cell signaling and the need for a new mechanics. Sci Signal (2009) 0.92
'On-the-fly' or 'generate-first' modeling? Nat Biotechnol (2005) 0.89
A bipolar clamp mechanism for activation of Jak-family protein tyrosine kinases. PLoS Comput Biol (2009) 0.87
GetBonNie for building, analyzing and sharing rule-based models. Bioinformatics (2009) 0.86
Dynamic pathway modeling of signal transduction networks: a domain-oriented approach. Methods Mol Biol (2008) 0.83
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Demographic history and rare allele sharing among human populations. Proc Natl Acad Sci U S A (2011) 7.36
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Resequencing 50 accessions of cultivated and wild rice yields markers for identifying agronomically important genes. Nat Biotechnol (2011) 4.84
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Rules for modeling signal-transduction systems. Sci STKE (2006) 3.86
Comparative and demographic analysis of orang-utan genomes. Nature (2011) 3.83
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
Rule-based modeling of biochemical systems with BioNetGen. Methods Mol Biol (2009) 3.47
BioNetGen: software for rule-based modeling of signal transduction based on the interactions of molecular domains. Bioinformatics (2004) 3.32
Global distribution of genomic diversity underscores rich complex history of continental human populations. Genome Res (2009) 2.76
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
A network model of early events in epidermal growth factor receptor signaling that accounts for combinatorial complexity. Biosystems (2005) 2.36
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Mathematical and computational models of immune-receptor signalling. Nat Rev Immunol (2004) 2.06
Design of gene circuits: lessons from bacteria. Nat Rev Genet (2004) 1.82
Investigation of early events in Fc epsilon RI-mediated signaling using a detailed mathematical model. J Immunol (2003) 1.78
Kinetic Monte Carlo method for rule-based modeling of biochemical networks. Phys Rev E Stat Nonlin Soft Matter Phys (2008) 1.76
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75
Targets of balancing selection in the human genome. Mol Biol Evol (2009) 1.69
PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther (2005) 1.67
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65
Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer (2011) 1.64
Homogenization of boundary conditions for surfaces with regular arrays of traps. J Chem Phys (2006) 1.63
Sloppiness, robustness, and evolvability in systems biology. Curr Opin Biotechnol (2008) 1.62
Boundary homogenization for trapping by patchy surfaces. J Chem Phys (2004) 1.50
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol (2006) 1.39
Sloppy-model universality class and the Vandermonde matrix. Phys Rev Lett (2006) 1.33
Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res (2012) 1.33
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res (2009) 1.29
On imposing detailed balance in complex reaction mechanisms. Biophys J (2006) 1.28
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther (2004) 1.24
Predominance of activated EGFR higher-order oligomers on the cell surface. Growth Factors (2008) 1.24
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther (2010) 1.20
Aggregation of membrane proteins by cytosolic cross-linkers: theory and simulation of the LAT-Grb2-SOS1 system. Biophys J (2009) 1.19
Simulation of large-scale rule-based models. Bioinformatics (2009) 1.18
Multiple functions of a feed-forward-loop gene circuit. J Mol Biol (2005) 1.17
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res (2011) 1.17
Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov (2011) 1.17
Stochastic effects and bistability in T cell receptor signaling. J Theor Biol (2008) 1.17
Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog (2013) 1.16
Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics (2013) 1.13
How to deal with large models? Mol Syst Biol (2009) 1.12
Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol (2006) 1.12
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
Modeling multivalent ligand-receptor interactions with steric constraints on configurations of cell-surface receptor aggregates. Biophys J (2010) 1.09
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat (2014) 1.08
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res (2002) 1.07
Design principles for regulator gene expression in a repressible gene circuit. J Mol Biol (2003) 1.07
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res (2006) 1.06
Improved predictions of transcription factor binding sites using physicochemical features of DNA. Nucleic Acids Res (2012) 1.06
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res (2006) 1.06
Modeling the early signaling events mediated by FcepsilonRI. Mol Immunol (2002) 1.05
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol (2008) 1.05
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther (2012) 1.05
Guidelines for visualizing and annotating rule-based models. Mol Biosyst (2011) 1.05
Rule-based modeling: a computational approach for studying biomolecular site dynamics in cell signaling systems. Wiley Interdiscip Rev Syst Biol Med (2013) 1.04
Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale J Biol Med (2009) 1.03
Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One (2012) 1.02
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol (2006) 1.02
Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. PLoS Comput Biol (2011) 1.02
A quantitative approach for studying IgE-FcepsilonRI aggregation. Mol Immunol (2002) 1.02
Carbon-fate maps for metabolic reactions. Bioinformatics (2007) 1.01
Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog (2013) 1.01
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res (2012) 1.01
UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther (2009) 1.01
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs (2010) 1.00
Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas (2008) 0.99
A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin (2011) 0.99
Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. Mol Cancer Res (2011) 0.98
A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One (2013) 0.98
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther (2008) 0.97
Exploring higher-order EGFR oligomerisation and phosphorylation--a combined experimental and theoretical approach. Mol Biosyst (2013) 0.96
Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther (2008) 0.96
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol (2010) 0.96
Recruitment of the adaptor protein Grb2 to EGFR tetramers. Biochemistry (2014) 0.95
Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma. PLoS One (2012) 0.95
Using sequence-specific chemical and structural properties of DNA to predict transcription factor binding sites. PLoS Comput Biol (2010) 0.95
Scaffold-mediated nucleation of protein signaling complexes: elementary principles. Math Biosci (2011) 0.95
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer (2012) 0.94
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs (2009) 0.93
The Brucella TIR-like protein TcpB interacts with the death domain of MyD88. Biochem Biophys Res Commun (2011) 0.93
Molecular characterization of interdigitating dendritic cell sarcoma. Rare Tumors (2010) 0.92